6Aissaoui N,Puymirat E,Tabone X ,et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995 USIC 2000, and FAST- MI French Nationwide Registries [ J ]. Eur Heart J, 2012, 33 : 2535-2543.
3OConnor CM, Rogers JG. Evidence for overturning the guidelines in cardiogenic shock[Jl. N Engl J Med, 2012, 367:1349-1350.
4Thiele H, Ailam B, Chatelher G, et al. Shock in acute myocardial infarction: the Cape Horn for trials [J] ? Eur Heart J, 2010, 31:1828-1835.
5Aissaoui N, Puymirat E, Tabone X, et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries[J]. Eur Heart J, 2012, 33:2535-2543.
6Abdel-Qadir HM, Ivanov J, Austin PC, et al. Temporal trends in eardiogenic shock treatment and outcomes among ontario patients with myocardial infarction between 1992 and 2008[J]. Circ Cardiovasc Qual Outcomes, 2011, 4: 440- 447.
7Thiele H, Zeymer U, Neumaam FJ, et al. Intraaortic balloon support for myo- cardial infarction with cardiogenic shock [ J ]. N Engl J Med, 2012, 367:1287- 1296.
8Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein Ⅱb/Ⅲ a blockade and outcome of cardiogenic shock complicating acute coronary syn- dromes without persistent ST-segment elevation [ J ]. J Am Coil Cardiol, 2000, 36: 685-692.
9Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends ( 1975 to 2005 ) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population- based perspective[J]. Circulation, 2009,119:1211-1219.
10Hands ME, Rutherford JD, Muller JE, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occur- rence, outcome and prognostic factors. The MILIS Study Group[J]. J Am Coil Cardiol, 1989,14:40-46 ; discussion 47-48.
